新聞Matthew Panuwat leaves Medivation as executive.On april 5, following an eight-day trial, a jury deliberated for just over two hours before finding that the SEC established by a preponderance of evidence that former Medivation executive Matthew Panuwat is liable for insider trading by trading not in Medivation's stock but instead its alleged competitor Incyte's stock (minutes after learning from his CEO that pfizer was close to acquiring Medivation).
新聞Medivation partnered with Astellas Pharma Inc on Jan 1st '05.Medivation Inc. licensed the patent and collaborated with Astellas to develop that research into a drug.
新聞Medivation has issues with breach of Panuwat’s fiduciary duties.The court next held that the SEC had sufficiently alleged a breach of Panuwat’s fiduciary duties to Medivation under the misappropriation theory of liability: he had used MNPI obtained from his employer for his personal benefit in violation of an agreement not to do so.
